NDAORALTABLETPriority Review
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
4
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 31m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVISTA (raloxifene hydrochloride) is an oral small-molecule selective estrogen receptor modulator (SERM) approved in 1997 for the prevention and treatment of osteoporosis in postmenopausal women. It works by selectively binding to estrogen receptors to increase bone mineral density and reduce fracture risk without the systemic effects of hormone replacement therapy.
$0.001BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with modest Part D utilization (2,802 claims in 2023), indicating a mature market with limited growth opportunities and likely smaller commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
Started Feb 2004
500 enrolled
Osteopenia
Long Term Effects of Raloxifene Treatment on Bone Quality
Started Apr 2003
31 enrolled
Osteoporosis, Post-Menopausal
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
Started Nov 1994
7,705 enrolled
Osteoporosis, Postmenopausal
EVA: Evista Alendronate Comparison
Osteoporosis
Career Relevance
Working on EVISTA offers stability in a mature, established brand but limited growth trajectory given its LOE-approaching status and modest utilization metrics (2,802 Part D claims in 2023). Career advancement opportunities are constrained; this role suits professionals seeking portfolio stewardship or preparation for generic/lifecycle management rather than high-growth commercial trajectory.
Worked on EVISTA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.